Search results for "Highlights"


 
Results 141 - 150 of about 369 for "Highlights".

Highlights

Risk of atrial fibrillation increased with worse glycemic control and renal complications. Among patients with normoalbuminuria, researchers found no excess risk of atrial fibrillation with an HbA1c less than 9.7% for men or 8.8% for women.
September 2017

Highlights

These recommendation are part of a consensus report by the two organizations that highlights major areas of care for clinicians managing adults with type 1 diabetes, focusing primarily on current and
October 2021

Highlights

An international expert group convened by the American Diabetes Association proposed that the criterion for diabetes remission be an HbA1c level below 6.5%, measured at least three months after glucose-lowering drugs are stopped.
September 2021

Highlights

The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.
September 2017

Highlights

The review included 189 randomized controlled trials that compared glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-2 inhibitors with placebo or other diabetes drugs in patients with type 2 diabetes.
July 2017

Highlights

Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.
October 2017

Highlights

Although it would seem to make sense that routine glucose self-monitoring provides better outcomes, this long-held belief is not supported by the data, said an editor's note accompanying the study.
July 2017

Highlights

health status, comorbid conditions, or glycemic control and highlight the fact that potential overtreatment of diabetes is a widespread issue.
May 2017

Highlights

Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
August 2017

Highlights

The observational analysis compared sodium-glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs in patients with type 2 diabetes in Denmark, Norway, and Sweden.
August 2017

Result Page: Prev   10   11   12   13   14   15   16   17   18   19   Next